Literature DB >> 19627659

Management of the statin-intolerant patient.

William H Smiley III1, Bobby V Khan, Laurence S Sperling.   

Abstract

Although the long- and short-term safety of statin therapy is well established, statin intolerance is common in clinical practice. Muscle symptoms are the most common side effect of statin therapy and are potentially the most hazardous and the most likely to reduce patient adherence. Clinicians can establish office protocols/procedures that will reduce the number of patients with statin intolerance. Genomic variations that result in statin-associated myopathy are likely. We await diagnostic and treatment options for this group. Alternative dosing options and the use of alternative statins are useful strategies for those with muscle symptoms. Therapeutic lifestyle changes are critical to achieving maximal risk reduction but remain difficult to implement. Presently available nonstatin lipid-lowering drugs (alone or in combination) do not have the established benefit of statins but do have potential benefit in select patients.

Entities:  

Year:  2009        PMID: 19627659     DOI: 10.1007/s11936-009-0027-3

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  24 in total

1.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

Authors:  James M McKenney; Michael H Davidson; Terry A Jacobson; John R Guyton
Journal:  Am J Cardiol       Date:  2006-02-28       Impact factor: 2.778

2.  Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia.

Authors:  Michael J Zema
Journal:  Am J Ther       Date:  2005 Jul-Aug       Impact factor: 2.688

3.  A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.

Authors:  Edwin J Whitney; Richard A Krasuski; Bradley E Personius; Joel E Michalek; Ara M Maranian; Mark W Kolasa; Erik Monick; B Gregory Brown; Antonio M Gotto
Journal:  Ann Intern Med       Date:  2005-01-18       Impact factor: 25.391

4.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

5.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Authors:  Eric Bruckert; Gilles Hayem; Sylvie Dejager; Caroline Yau; Bernard Bégaud
Journal:  Cardiovasc Drugs Ther       Date:  2005-12       Impact factor: 3.727

7.  Effect of coenzyme q10 on myopathic symptoms in patients treated with statins.

Authors:  Giuseppe Caso; Patricia Kelly; Margaret A McNurlan; William E Lawson
Journal:  Am J Cardiol       Date:  2007-04-03       Impact factor: 2.778

8.  Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein.

Authors:  David J A Jenkins; Cyril W C Kendall; Augustine Marchie; Dorothea A Faulkner; Julia M W Wong; Russell de Souza; Azadeh Emam; Tina L Parker; Edward Vidgen; Karen G Lapsley; Elke A Trautwein; Robert G Josse; Lawrence A Leiter; Philip W Connelly
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia.

Authors:  Antonios M Xydakis; John R Guyton; Philip Chiou; Judy L Stein; Peter H Jones; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2004-09-15       Impact factor: 2.778

10.  Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech
Journal:  Diabetes Care       Date:  2008-11-04       Impact factor: 19.112

View more
  4 in total

Review 1.  Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.

Authors:  Tiffany Thomas; Henry Ginsberg
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

Review 2.  Update on toxic myopathies.

Authors:  F L Mastaglia; M Needham
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

Review 3.  Statin-induced Liver Injury Patterns: A Clinical Review.

Authors:  Leon D Averbukh; Alla Turshudzhyan; David C Wu; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2022-01-10

Review 4.  Interdependence of Anti-Inflammatory and Antioxidant Properties of Squalene-Implication for Cardiovascular Health.

Authors:  Nurul 'Izzah Ibrahim; Isa Naina Mohamed
Journal:  Life (Basel)       Date:  2021-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.